Bartering for time: realism versus hope.

The issue of third-party reimbursement also came up. “We hope the guidelines will help with reimbursement with some of these therapies by becoming standard practice,” Denlinger said. “But we don’t yet know.” Similarly, Philippe Spiess, M.D., genitourinary oncologist at H. Lee Moffitt Cancer Center in Tampa, Fla., and a member of NCCN’s bladder/penile cancer panel, said that uncertainty surrounds reimbursement for penile cancer as well, especially for new organ-preserving therapies, such as imiquimod or 5-fluorouracil cream, in the treatment of early disease.